LIBTAYO may help
LIBTAYO was studied in a clinical
trial which included patients with
advanced BCC after they
were treated with an HHI.
In the trial, 27 out of 84 patients (32%) saw an improvement in their locally advanced BCC with LIBTAYO.These patients had responses that lasted between 2.1 months and 36.8+ months. 13 out of 54 patients (24%) saw an improvement in their metastatic BCC with LIBTAYO. These patients had responses that lasted between 4.8 months and 25.8+ months. Plus sign [+] means this patient was still responding to treatment at their last assessment.
What is advanced BCC?
Learn more about how BCC can progress to advanced disease.